MELBOURNE, Australia and INDIANAPOLIS, March 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces ...
Telix Pharmaceuticals has announced positive early-stage results from its global phase 3 trial of TLX591, an experimental treatment for advanced prostate cancer. The initial phase of the trial, ...
Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the full year and fourth quarter 2025, and provided an overview of recent business highlights. “We are pleased with our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results